Piper Jaffray Upgrades Acorda Therapeutics To Neutral, PT Raised To $30


20-Year Pro Trader Reveals His "MoneyLine"

Ditch your indicators and use the "MoneyLine." A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.


Piper Jaffray has upgraded Acorda Therapeutics (NASDAQ: ACOR) from Underweight to Neutral and has raised the price target from $21 to $30.

20-Year Pro Trader Reveals His "MoneyLine"

Ditch your indicators and use the "MoneyLine." A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.


ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

Posted In: UpgradesPrice TargetAnalyst RatingsAcorda TherapeuticsBiotechnologyHealth CarePiper Jaffray